What does Rein Therapeutics (NASDAQ:RNTX) 25% RENEW enrollment milestone mean?

Rein Therapeutics (NASDAQ:RNTX) has enrolled more than 25% of the approximately 120 patients planned for its Phase 2 RENEW trial of LTI-03 in idiopathic pulmonary fibrosis. The company says enrollment is currently ahead of schedule.

When does Rein Therapeutics (NASDAQ:RNTX) expect RENEW trial data?

Rein Therapeutics (NASDAQ:RNTX) says it remains on track to report interim RENEW data during the second half of 2026. The study is now enrolling patients across five countries.

What are Rein Therapeutics (NASDAQ:RNTX) Q2 2026 financial results?

Rein Therapeutics (NASDAQ:RNTX) reported a Q2 net loss of $6.4 million, compared with $6.8 million a year earlier, while R&D expense fell to $3.6 million from $4.3 million.

How is Rein Therapeutics (NASDAQ:RNTX) funding the RENEW trial?

Rein Therapeutics (NASDAQ:RNTX) completed a $57.5 million underwritten public offering, selling 57.5 million shares at $1.00 each. The company expects the financing and existing cash to fully fund RENEW and support operations into Q1 2028.

Health

Image for illustrative purposes only. Not a real photo.

Rein Therapeutics RENEW enrollment passes 25% mark

Written by Liezl GambePublished Aug 14, 2026, 10:56 AM

Rein Therapeutics said its Phase 2 RENEW trial has passed 25% of planned enrollment of about 120 patients.
RNTX shares were unchanged at about $0.79 in premarket trading following the results.
The company says its $57.5 million public offering and existing cash should fund operations into the first quarter of 2028.

Rein Therapeutics (NASDAQ:RNTX) said its Phase 2 RENEW trial of inhaled LTI-03 has surpassed 25% of planned enrollment of approximately 120 patients.

The IPF study is enrolling across the U.S., U.K., Australia, Germany and Poland, with Rein saying enrollment is ahead of schedule and interim data remains planned for the second half of 2026.

Rein reported $43.6 million in cash and investments, while Q2 R&D expense fell to $3.6 million and net loss narrowed to $6.4 million.

Following the announcement, Rein Therapeutics' share price was unchanged at about $0.79 in premarket trading.

Meanwhile, Rein completed a $57.5 million underwritten offering in May, which the company expects will fully finance RENEW and support operations into the first quarter of 2028.

A first-in-human LTI-03 study published in Nature Communications on July 31 reported reductions in several markers associated with lung scarring and inflammation.